Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer

Yoshihisa Sakaguchi, Akira Kabashima, Keishi Okita, Yasutomo Ojima, Shinji Yamamura, Takashi Nishizaki, Hideya Tashiro, Toshimitsu Matsusaka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background. Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy. Methods. Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80mg/m2. In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60mg/m2, was infused on day 8. Results. The incidence of adverse reactions of more than grade 3 was 22.5% in the S-1 group and 43.5% in the S-1/ CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9% in the S-1 group, and 36.8% in the S-1/CDDP group. The combination of S-1 with CDDP had better effects on the primary lesion and on differentiated-type carcinoma than S-1 alone. However, there was no difference in survival between the two patient groups. The median survival time after the initiation of treatment in the S-1 group was 322 days, and that in the S-1/CDDP group was 319 days. Conclusions. Our results suggest that the combination of CDDP with S-1 does not improve the long-term outcome of S-1 therapy.

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalGastric Cancer
Volume8
Issue number2
DOIs
Publication statusPublished - May 1 2005

Fingerprint

Cisplatin
Stomach Neoplasms
Therapeutics
Survival
S 1 (combination)
Carcinoma
Drug Therapy
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Sakaguchi, Y., Kabashima, A., Okita, K., Ojima, Y., Yamamura, S., Nishizaki, T., ... Matsusaka, T. (2005). Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer. Gastric Cancer, 8(2), 111-116. https://doi.org/10.1007/s10120-004-0313-4

Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer. / Sakaguchi, Yoshihisa; Kabashima, Akira; Okita, Keishi; Ojima, Yasutomo; Yamamura, Shinji; Nishizaki, Takashi; Tashiro, Hideya; Matsusaka, Toshimitsu.

In: Gastric Cancer, Vol. 8, No. 2, 01.05.2005, p. 111-116.

Research output: Contribution to journalArticle

Sakaguchi, Y, Kabashima, A, Okita, K, Ojima, Y, Yamamura, S, Nishizaki, T, Tashiro, H & Matsusaka, T 2005, 'Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer', Gastric Cancer, vol. 8, no. 2, pp. 111-116. https://doi.org/10.1007/s10120-004-0313-4
Sakaguchi, Yoshihisa ; Kabashima, Akira ; Okita, Keishi ; Ojima, Yasutomo ; Yamamura, Shinji ; Nishizaki, Takashi ; Tashiro, Hideya ; Matsusaka, Toshimitsu. / Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer. In: Gastric Cancer. 2005 ; Vol. 8, No. 2. pp. 111-116.
@article{23e02fa38b644d59b33e7cdbfcffcde3,
title = "Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer",
abstract = "Background. Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy. Methods. Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80mg/m2. In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60mg/m2, was infused on day 8. Results. The incidence of adverse reactions of more than grade 3 was 22.5{\%} in the S-1 group and 43.5{\%} in the S-1/ CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9{\%} in the S-1 group, and 36.8{\%} in the S-1/CDDP group. The combination of S-1 with CDDP had better effects on the primary lesion and on differentiated-type carcinoma than S-1 alone. However, there was no difference in survival between the two patient groups. The median survival time after the initiation of treatment in the S-1 group was 322 days, and that in the S-1/CDDP group was 319 days. Conclusions. Our results suggest that the combination of CDDP with S-1 does not improve the long-term outcome of S-1 therapy.",
author = "Yoshihisa Sakaguchi and Akira Kabashima and Keishi Okita and Yasutomo Ojima and Shinji Yamamura and Takashi Nishizaki and Hideya Tashiro and Toshimitsu Matsusaka",
year = "2005",
month = "5",
day = "1",
doi = "10.1007/s10120-004-0313-4",
language = "English",
volume = "8",
pages = "111--116",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer

AU - Sakaguchi, Yoshihisa

AU - Kabashima, Akira

AU - Okita, Keishi

AU - Ojima, Yasutomo

AU - Yamamura, Shinji

AU - Nishizaki, Takashi

AU - Tashiro, Hideya

AU - Matsusaka, Toshimitsu

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Background. Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy. Methods. Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80mg/m2. In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60mg/m2, was infused on day 8. Results. The incidence of adverse reactions of more than grade 3 was 22.5% in the S-1 group and 43.5% in the S-1/ CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9% in the S-1 group, and 36.8% in the S-1/CDDP group. The combination of S-1 with CDDP had better effects on the primary lesion and on differentiated-type carcinoma than S-1 alone. However, there was no difference in survival between the two patient groups. The median survival time after the initiation of treatment in the S-1 group was 322 days, and that in the S-1/CDDP group was 319 days. Conclusions. Our results suggest that the combination of CDDP with S-1 does not improve the long-term outcome of S-1 therapy.

AB - Background. Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy. Methods. Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80mg/m2. In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60mg/m2, was infused on day 8. Results. The incidence of adverse reactions of more than grade 3 was 22.5% in the S-1 group and 43.5% in the S-1/ CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9% in the S-1 group, and 36.8% in the S-1/CDDP group. The combination of S-1 with CDDP had better effects on the primary lesion and on differentiated-type carcinoma than S-1 alone. However, there was no difference in survival between the two patient groups. The median survival time after the initiation of treatment in the S-1 group was 322 days, and that in the S-1/CDDP group was 319 days. Conclusions. Our results suggest that the combination of CDDP with S-1 does not improve the long-term outcome of S-1 therapy.

UR - http://www.scopus.com/inward/record.url?scp=18544383587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544383587&partnerID=8YFLogxK

U2 - 10.1007/s10120-004-0313-4

DO - 10.1007/s10120-004-0313-4

M3 - Article

C2 - 15864718

AN - SCOPUS:18544383587

VL - 8

SP - 111

EP - 116

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 2

ER -